Portions of these findings were presented at the 2007 ASCO Annual Meeting. The study from which the results were drawn was designed and conducted by independent investigators at Evanston Northwestern Healthcare and NCCN.
The authors have disclosed that they have no financial interests, arrangements, or affiliations with the manufacturers of any products discussed in this article or their competitors. Support for the study was provided by grants from the following pharmaceutical companies: Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Centocor, Cell Therapeutics, Inc., Eli Lilly and Company, Genentech, GlaxoSmithKline, Merck & Co., Novartis, Ortho Biotech, Pfizer, sanofi-aventis, and Takeda Pharmaceuticals.
Guidance for Industry: patient-reported outcome measures: use in medical product development to support labeling claims. U.S. Food and Drug Administration Web site. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf. Accessed January 20 2011.
CellaDFPaulDYountS. What are the most important symptom targets when treating advanced cancer? A survey of providers in the National Comprehensive Cancer Network (NCCN). Cancer Invest2003;21:526–535.
AaronsonNKAhmedzaiSBergmanB. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst1993;85:365–376.
CellaDFTulskyDSGrayG. The Functional Assessment of Cancer Therapy (FACT) Scale: development and validation of the general measure. J Clin Oncol1993;11:570–579.
SchipperHClinchJMcMurrayA. Measuring the quality of life of cancer patients: the Functional Living Index-Cancer: development and validation. J Clin Oncol1984;2:472–483.
TaylorKMMacdonaldKGBezakA. Physicians' perspective on quality of life: an exploratory study of oncologists. Qual Life Res1996;5:5–14.
BezjakATaylorKMNgP. Quality-of-life information and clinical practice: the oncologist's perspective. Cancer Prev Control1998;2:230–235.
DeyoRAPatrickDL. Barriers to the use of health status measures in clinical investigation, patient care, and policy research. Med Care1989;27(Suppl):S254–268.
WilsonIBClearyPD. Linking clinical variables with health-related quality of life: a conceptual model of patient outcomes. JAMA1995;32:59–65.
RothermichEAPathakDS. References for health-related quality of life claims in prescription drug advertisements. Am J Health Syst Pharm1997;32:2596–2599.
Quality Of Life Subcommittee of the Oncologic Drugs Advisory CommitteeFebruary102000. U.S. Food and Drug Administration Web site. Available at: http://www.fda.gov/ohrms/dockets/ac/00/slides/3591s1.htm. Accessed January 20 2011.
LeidyNKRevickiDAGenestéB. Recommendations for evaluating the validity of quality of life claims for labeling and promotion. Value Health1999;32:113–127.
PortenoyRKThalerHTKornblithAB. Symptom prevalence, characteristics and distress in a cancer population. Qual Life Res1994a;3:183–189.
PortenoyRKThalerHTKornblithAB. The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. Eur J Cancer1994b;30A:1326–1336.
SutherlandHJLockwoodGABoydNF. Ratings of the importance of quality of life variables: therapeutic implications for patients with metastatic breast cancer. J Clin Epidemiol1990;32:661–666.
BrunelliCCostantiniMDi GiulioP. Quality of life evaluation: when do terminal cancer patients and health-care providers agree?J Pain Symptom Manage1998;32:151–158.
JusticeACRabeneckLHaysRD. Sensitivity, specificity, reliability, and clinical validity of provider-reported symptoms: a comparison with self-reported symptoms. J AIDS1999;32:126–133.
NekolaichukCBrueraESpachynskiK. A comparison of patient and proxy symptom assessments in advanced cancer patients. Palliat Med1999;32:311–323.
StephensRJHopwoodPGirlingDJ. Randomized trials with quality of life endpoints: are doctors' ratings of patients' physical symptoms interchangeable with patients' self-ratings?Qual Life Res1997;32:225–236.
StromgrenASGroenvoldMSorensenA. Symptom recognition in advanced cancer: a comparison of nursing records against patient self-rating. Acta Anaesthesiol2001;32:1080–1085.
LampicCNordinKSjodenP. Agreement between cancer patients and their physicians in the assessment of patient anxiety at follow-up visits. Psychooncology1995;32:301–310.
RaoDButtZRosenbloomS. A comparison of the Renal Cell Carcinoma Symptom Index (RCC-SI) and the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI). J Pain Symptom Manage2009;32:291–298.